2022 annual financial data
Edgewise Therapeutics 2022 Net income growth
Direct answer
Net income growth was 63.46%.
Operating income was -22,079,000 USD and net income was -15,397,000 USD.
Operating cash flow was -52,635,000 USD.
Get free Edgewise Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -22,079,000 USD
- Net income
- -15,397,000 USD
- Operating cash flow
- -52,635,000 USD